|
Variable
|
Leiden EAC
|
BARFOT
|
ESPOIR
|
Umeå
|
Lund
|
|---|
|
Total number of patients
|
1244
|
839
|
632
|
459
|
147
|
|
Age, mean (SD)
|
56.6 (15.5)
|
56.7 (15.4)
|
48.9 (12.2)
|
53.9 (14.5)
|
50.7 (11.5)
|
|
Female, n (%)
|
827 (66.5)
|
538 (64.1)
|
484 (76.6)
|
321 (69.9)
|
98 (66.7)
|
|
Symptom durationa (weeks), median (IQR)
|
18.3 (9–36)
|
26.1 (17–39)
|
21.4 (13–33)
|
28.0 (16–39)
|
43.3 (28–61)
|
|
Smoking at baseline, n (%)
|
308 (25.9)
|
227 (27.1)
|
137 (21.7)
|
107 (23.9)
|
39 (30.7)
|
|
ACPA+, n (%)
|
638 (52.8)
|
418 (55.0)
|
291 (46.0)
|
339 (73.9)
|
114 (80.3)
|
|
RF+, n (%)
|
715 (58.0)
|
453 (59.6)
|
344 (54.4)
|
362 (79.0)
|
115 (81.0)
|
|
Anti-CarP+, n (%)
|
474 (42.3)
|
280 (34.7)
|
NA
|
NA
|
NA
|
|
ESR (mm/h), median (IQR)
|
31 (16–50)
|
30 (15–50)
|
23 (12–41)
|
22 (12–39)
|
28 (13–50)
|
|
CRP (mg/L), median (IQR)
|
14 (6–35.5)
|
19 (7–47.5)
|
10 (3–26)
|
10 (8–25)
|
15 (0–45.5)
|
|
SJC, median (IQR)
|
5 (3–10)
|
10 (6–14)
|
7 (4–11)
|
6 (3–10)
|
6 (3–10)
|
|
TJC, median (IQR)
|
6 (2–11)
|
7 (3–12)
|
8 (4–14)
|
5 (2–10)
|
7 (4–11)
|
-
n number of patients, SD standard deviation, IQR interquartile range, ACPA anti-citrullinated protein antibodies, RF rheumatoid factor, anti-CarP antibodies ESR erythrocyte sedimentation rate, CRP C-reactive protein, TJC tender joint count based on 68 joints (Leiden EAC) or on 28 joints (BARFOT, ESPOIR, Umeå) or Ritchie index (Lund), SJC swollen joint count based on 66 joints (Leiden EAC) or on 28 joints (BARFOT, ESPOIR, Umeå) or on 50 joints (Lund), NA not available
-
aTime between symptom onset and inclusion in cohort
